Rod Raynovich's  Instablog

Rod Raynovich
Send Message
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 30 years executive experience including Abbott and JNJ and has been involved three successful start-ups. He has a B.S, from Penn State University and an MBA from... More
My company:
Raygent Capital
My blog:
  • Rayno Life Science Update-Macro Rules, Risk Off 0 comments
    May 9, 2012 2:29 PM

    Market Off Its Lows Today-Consumer Cyclical and Technology Outperforming Healthcare

    The market continues to be weak with the NASDAQ entering its 5th day of the sell-off down 4.29% but the QQQ ($64.29) NASDAQ-100 has recovered from lows today. The ETF IBB ($64.32) has fared better down only 1.92% over five days and still up 18% YTD off its 2012 and all time high of $126.65. The XBI is running close by tracking the IBB but slightly underperforming over the past 5 days. (Fast Money-CNBC contributors have been pushing biotech and XBI lately which makes us curious but skeptical). The sector got a slight boost on Monday with clinical news from Vertex(NASDAQ:VRTX) on favorable data for its cystic fibrosis therapy, gapping the stock up 57%. many ETF's and biotech funds have a 3-4% weighting in VRTX which has been a laggard due to competitive HCV therapies to its INCIVEK drug. (We recommended VRTX as a trade under $40).

    The biotech sector has outperformed the NASDAQ-100 by about 6% over the past month as it is less affected by MACRO events and boosted by good clinical news as well as the longer term M&A trend. Moreover AAPL is down 10% over one month so that contributes to the weakness of the QQQ. With AAPL stabilizing today up $4 we could see the QQQ outperforming the IBB. We would not add to positions in large cap biotech at this time due to a frothy tape (see VRTX) and overweight hedge fund who are MO players that will need to take profits.

    Our mid-cap biopharmaceutical index is down 1% with Dendreon (DNDN $9 ) up 2.6% on volume of 5.5M and DynaVax (DVAX $4.05) was down 20% on volume of 20.5 M shares after they announced an offering of 17.5M shares at $4.25.

    On May 15 both BG Medicine (BGMD $4.03) and Vermillion, Inc. (VRML $2.11) will report sales and earnings. We reported on April 4 that these two companies were emerging players in biomarkers and offered a challenge as to who might be more successful by year-end 2012 as revenues build and deals are announced. Over one month the VRML stock is up 3.94% while the BGMD stock is down 40%. Vermillion stock trades at unusually high volume of 500k shares/day for a micro-cap. The BGMD volume is in the 40k shares/day range.

    Tools and Diagnostics stocks have been laggards but two small caps on our focus list Response Genetics (RGDX $1.99) and Sequenom (SQNM $5.32) are up today.

    Disclosure: I am long AAPL, DVAX, RGDX.

Back To Rod Raynovich's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.